20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
暂无分享，去创建一个
I. Ray-Coquard | D. Lorusso | V. Makker | E. Colomba | S. Baron-Hay | A. Martin Nguyen | R. Shapira-Frommer | N. Colombo | K. Fujiwara | A. Casado Herráez | J. McKenzie | Y. Kim | S. Pignata | D. Miller | R. Massaad | M. McCormack | Q. Zhao | A. Santin | V. Prabhu